July 29, 2011 -- Shenzhen Hepalink Pharmaceutical, a company that makes APIs for the blood thinner heparin, said 2011 first-half results were hurt by higher costs and lower revenues. Hepalink reported first-half net income dropped 40% to 362 million RMB ($56.2 million) on revenues that fell 13% to 1.6 billion RMB ($249 million). Earnings per share were 44% lower at .45 RMB. Hepalink derives the majority of its revenues from ex-China sales of its heparin products. More details....
Stock Symbol: (SHE: 002399)
